The following tables were reproduced from [Circulation: Cardiovascular Quality and Outcomes, Harlan M. Krumholz, Cary P. Gross, Katrina L. Blount, Jessica D. Ritchie, Beth Hodshon, Richard Lehman, and Joseph S. Ross, 7, 499-504, 2014] with permission from BMJ Publishing Group Ltd.
TABLE D-1 Top 1 to 6 Pharmaceutical Companies, Ranked by 2013 Market Capitalization
Data-Sharing Parameters | PhRMA EFPIA Guidelines | Janssen Pharmaceuticals | Pfizer | |
Clinical trial data available for sharing |
|
|
|
|
Data not available for sharing |
|
|
|
|
Types of data provided |
|
|
|
Novartis | Roche | Sanofi | Merck | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Data-Sharing Parameters | PhRMA EFPIA Guidelines | Janssen Pharmaceuticals | Pfizer | |
Availability of CRFs | NA |
|
|
|
Data access fee | NA |
|
|
|
Data application requirements of note |
|
|
|
Novartis | Roche | Sanofi | Merck | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Data-Sharing Parameters | PhRMA EFPIA Guidelines | Janssen Pharmaceuticals | Pfizer | |
Data request review process |
|
|
|
Novartis | Roche | Sanofi | Merck | |
|
|
|
|
NOTE: COI indicates conflict of interest; CRF, case report form; CSR, clinical study report; CV, curriculum vitae; EFPIA, European Federation of Pharmaceutical Industries and Associations; EU, European Union; ICF, informed consent form; IPD, individual patient-level data; IRB, institutional review board; PhRMA, Pharmaceutical Research and Manufacturers of America; and YODA, Yale University Open Data Access.
TABLE D-2 Top 7 to 12 Pharmaceutical Companies, Ranked by 2013 Market Capitalization
Data-Sharing Parameters | PhRMA EFPIA Guidelines | GlaxoSmithKline | Bayer | |
Clinical trial data available for sharing |
|
|
|
|
Data not available for sharing |
|
|
|
* Independent Review Panel is shared by ClinicalStudyDataRequest.com companies.
** Process for making CSR summaries publicly available is being developed.
† The YODA Project data request website is being developed. Those wishing to submit a request for Janssen data can visit http://www.clinicaltrialstudytransparency.com in the interim.
Bristol-Myers Squibb | AbbVie | Eli Lilly | AstraZeneca | |
|
|
|
|
|
|
|
|
|
Data-Sharing Parameters | PhRMA EFPIA Guidelines | GlaxoSmithKline | Bayer | |
Types of data provided |
|
|
|
|
Availability of CRFs | NA |
|
|
|
Data access fee | NA |
|
|
|
Data application requirements of note |
|
|
|
Bristol-Myers Squibb | AbbVie | Eli Lilly | AstraZeneca | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Data-Sharing Parameters | PhRMA EFPIA Guidelines | GlaxoSmithKline | Bayer | |
Data request review process |
|
|
|
Bristol-Myers Squibb | AbbVie | Eli Lilly | AstraZeneca | |
|
|
|
|
|
NOTE: COI indicates conflict of interest; CRF, case report form; CSR, clinical study report; CV, curriculum vitae; DUA, data use agreement; EFPIA, European Federation of Pharmaceutical Industries and Associations; EU, European Union; GSK, GlaxoSmithKline; ICF, informed consent form; IPD, individual patient-level data; IRB, institutional review board; and PhRMA, Pharmaceutical Research and Manufacturers of America.
* Independent Review Panel is shared by ClinicalStudyDataRequest.com companies.